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Stress-responsive microRNAsAdministration of Lactobacillus gasseri CP2305 for 4 weeks improved stress-associated behaviours in
healthy young adults and clinical symptoms in patients with irritable bowel syndrome. The present study
was designed to confirm the stress-relieving effects of heat-inactivated, washed CP2305 (paraprobiotic
CP2305) on 69 sixth-year medical students (40 males and 29 females) preparing to take the national
examination for medical practitioners. Administration of the paraprobiotic CP2305 for 12 weeks signifi-
cantly improved sleep quality assessed by both the Pittsburgh Sleep Quality Index and a one-channel
sleep electroencephalogram during the pre-examination period compared with that of the placebo
administration. The paraprobiotic CP2305 administration also prevented increases in basal salivary cor-
tisol release and expression of stress-responsive microRNAs (miR-144 and miR-144⁄). In addition to the
improvement in parasympathetic nerve activity, the paraprobiotic CP2305 normalized the bowel habits
under the stressful conditions. Based on these results, we propose that paraprobiotic CP2305 may be used
as a para-psychobiotic.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
There is growing evidence that the bidirectional communica-
tion between the brain and the gut, called ‘‘the gut-brain axis”,
plays a potential role in the maintenance of the brain function as
well as the gut homeostasis (Aziz & Thompson, 1998). Recently, a
number of studies with experimental animals have shown that
gut microbes are crucial factors for normal neurodevelopment
and behaviour (Cryan & Dinan, 2012; Sampson & Mazmanian,
2015). At the same time, distinct types of microbes, such as orallyadministered probiotics, have been shown to modify the gut-brain
axis and control the stress response (Bercik, Collins, & Verdu,
2012). These recent findings suggest that probiotics may have a
therapeutic role in the management of mood disorders, such as
major depression or anxiety disorders, by regulating ‘‘the
microbiota-gut-brain axis” (Dinan, Stanton, & Cryan, 2013).
Psychological stress causes a negative effect on the composition
of the intestinal microbiota (Suzuki, Harasawa, Yoshitake, &
Mitsuoka, 1983) and enteric environment and consequently
increases the risk for the development of functional disorders, such
as irritable bowel syndrome (IBS) (Wood, 2002). Several lines of
evidence from animal and human studies have shown that intesti-
nal inhabitants and orally introduced external microbes could
change the activities of the autonomic nervous system and modu-
late gut functions (Obata & Pachnis, 2016; Tougas, 2000), serotonin
biosynthesis (Yano et al., 2015), and mental health status
(Sampson & Mazmanian, 2015). The living microbes used for these
treatments are called ‘‘psychobiotics” (Dinan et al., 2013). The use
of the paraprobiotic instead of probiotic CP2305 has potential ben-
efits for the production of manufactured products. In addition, the
heat-inactivated, washed bacterial cells is a starting material for
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living, inactivated beneficial microbe(s) for this purpose has not
yet been reported.
We originally isolated a unique Lactobacillus gasseri strain
CP2305 (CP2305) from stool samples of a healthy volunteer
(Sawada et al., 2016). CP2305 colonized the digestive tracts of
approximately 40% of volunteers after 3-time oral administration
at a dose of 1.0  1011 CFU (Sawada et al., 2016). Recently, we
reported that CP2305 could relieve stress-associated behaviours
in healthy young adults (Sawada et al., 2017) and improve clinical
symptoms of IBS (Nobutani et al., 2017). IBS symptoms are closely
associated with psychosocial stress. Subsequently, we showed that
heat-inactivated CP2305 improved stool properties and bowel
habits and balanced the autonomic nervous activity of healthy vol-
unteers (Sugawara et al., 2016).
Based on these findings, this study was designed to assess para-
probiotic CP2305 as a stress-relieving para-psychobiotic. For this
purpose, we enrolled 69 six-year undergraduate medical students
preparing for the national examination for medical practitioners.
We conducted a double-blinded, placebo-controlled, parallel-
group trial. The participants daily took paraprobiotic CP2305 or
placebo for 12 weeks during the pre-examination period. This per-
iod has a significant impact on psychological state of medical stu-
dents and represents a suitable model for the analysis of chronic
psychological stress (Honda et al., 2013; Kurokawa et al., 2011).
In addition to psychological measures, we assessed biological
stress responses by measuring basal salivary cortisol levels, sleep
electroencephalogram (EEG), autonomic nervous activities, and
stress-responsive microRNAs in circulating leukocytes.
2. Materials and methods
2.1. Study design
The present study was approved by the Institutional Review
Board of Tokushima University Hospital, Tokushima, Japan.
Informed consent was also certified by this committee. This study
was performed in accordance with the ethical standards laid down
in the 1964 Declaration of Helsinki. We recruited 69 sixth-year
undergraduate medical students (40 males and 29 females with a
mean age of 25.0 years) at Tokushima University in Tokushima,
Japan. After the experimental procedures were fully explained,
written informed consent was obtained from all participants. AllFig. 1. Schedule for the clinical trial. Participants were divided into 2 groups. Biological
6 weeks after the start of ingestion, at the end of the ingestion period and at the end ofstudents were in good physical health, taking no medication for
at least three months prior to study enrollment and during the
experimental period, and had no history of psychiatric or somatic
diseases, either past or present. Female students were not taking
hormonal contraceptives. All subjects were nonsmokers. None of
the students had allergies to milk or other foods.
The clinical trial was performed from November 2nd, 2015, to
February, 5th, 2016. The students were in the preparation period
for the national examination for medical practitioners (Fig. 1). The
students were randomly divided into 2 groups (Table 1). Partici-
pants allocated to group 1 (n = 35; m/f = 20/15) received the
placebo beverage once per day throughout the 12-week manipula-
tion period. Participants allocated to group 2 (n = 34; m/f = 20/14,
Table 1) consumed the beverage containing the paraprobiotic
CP2305 in the same manner. Daily consumption was self-
recorded in a diary to assess the compliance rate of the participants.
During the trial, the subjects complied with dietary restrictions to
avoid the consumption of other fermented milks, fermented foods,
beverages containing living lactic acid bacteria, and other probiotic
or prebiotic products. Medications and hospital visits were allowed
and recorded in a diary if these events occurred.
2.2. Experimental beverages
A heat-inactivated CP2305 cell product was prepared as
described below. CP2305 was cultured at 37 C for 18 h in an orig-
inal, food ingredients-based medium containing glucose, casein,
fish protein peptone, yeast extract, a pH adjuster, and an emulsi-
fier. The cultured CP2305 cells were concentrated using a ceramic
filter, washed with excessive water, pasteurized at 90 C, and
freeze dried.
Test beverages containing CP2305 were prepared by blending
high-fructose corn syrup, powdered skim milk, lactic acid, soybean
polysaccharide, pectin, sodium citrate, flavours, sweeteners, and
the heat-inactivated, washed CP2305 powder corresponding to
1  1010 bacterial cells in water, followed by pasteurization and
packing into a 200-mL container. Placebo beverages were prepared
using the same formula and procedure as for the CP2305 beverage,
except this product did not contain the CP2305 powder. The nutri-
tional content of the test and placebo beverages are described as
follows. The CP2305 beverages provided a total of 214 kJ/d
(51 kcal/d), 1.8 g protein, 11 g carbohydrates, and 73 mg sodium
chloride in 200 mL. The placebo beverage provided a total ofsamples and questionnaire responses were obtained prior to the start of treatment,
the post-ingestion period.
Table 1
The clinical characteristics of the CP2305 and placebo groups.
Measurements Placebo CP2305
Whole group Male Female Whole group Male Female
Numbers 35 21 14 34 19 15
Years of age 25.1 ± 0.4 (22–35) 25.7 ± 0.6 (23–35) 24.2 ± 0.4 (22–27) 24.9 ± 0.3 (23–32) 25.3 ± 0.5 (23–32) 24.3 ± 0.27 (23–27)
Exercise habitsa 3.7 ± 0.1 (2–4) 3.6 ± 0.1 (3–4) 3.6 ± 0.1 (3–4) 3.6 ± 0.1 (2–4) 3.5 ± 0.1 (2–4) 3.8 ± 0.1 (3–4)
Height (cm) 167.8 ± 1.4 (154–189) 172.6 ± 1.2 (165–189) 160.5 ± 1.3 (154–168) 166.5 ± 1.3 (155–181) 171.0 ± 1.3 (158–181) 160.8 ± 1.2 (155–170)
Weight (kg) 58.9 ± 1.7 (43–81) 63.9 ± 1.8 (50–81) 51.4 ± 1.9 (43–68) 58.6 ± 1.5 (43–81) 64.4 ± 1.6 (54–78) 51.2 ± 1.3 (44–60)
BMI (kg/m2) 20.8 ± 0.9 (16.5–25.3) 21.4 ± 0.4 (17.9–25.3) 19.9 ± 0.7 (16.5–26.6) 21.1 ± 0.4 (18.1–27.0) 22.1 ± 0.6 (18.1–27.0) 19.8 ± 0.4 (18.1–23.4)
GHQ total
(Goldberg)
5.6 ± 0.9 (0–19) 4.2 ± 1.2 (0–19) 7.6 ± 1.3 (0–14) 5.8 ± 0.8 (0–17) 4.8 ± 1.3 (0–17) 7.1 ± 0.9 (1–13)
STAI state anxiety 41.7 ± 2.2 (21–64) 38.0 ± 2.8 (21–63) 47.3 ± 3.3 (26–64) 40.1 ± 1.9 (22–62) 35.7 ± 2.3 (22–57) 45.7 ± 2.5 (25–62)
STAI trait anxiety 44.4 ± 2.1 (20–67) 40.2 ± 2.6 (20–65) 50.7 ± 2.8 (34–67) 43.8 ± 2.3 (21–69) 39.7 ± 3.1 (21–68) 49.0 ± 2.9 (30–69)
PSQI 4.1 ± 0.5 (0–12) 3.8 ± 0.6 (0–12) 4.6 ± 0.7 (1–9) 4.9 ± 0.5 (0–12) 4.8 ± 0.7 (0–17) 4.9 ± 0.6 (0–12)
HADS anxiety 6.4 ± 0.8 (0–16) 5.1 ± 0.9 (0–14) 8.4 ± 1.1 (1–16) 6.3 ± 0.8 (0–16) 5.3 ± 1.0 (0–13) 7.6 ± 0.8 (0–16)
HADS depression 6.8 ± 0.7 (0–17) 6.3 ± 1.0 (0–17) 7.6 ± 0.9 (1–14) 6.3 ± 0.6 (0–12) 5.3 ± 0.8 (0–12) 7.5 ± 0.7 (1–11)
Data are expressed as the mean ± SEM.
Numbers in parentheses are the range of sample data.
a Exercise habits were evaluated by the records of the four-grade questionnaire. The higher the grade, the less the exercise habit is shown.
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sodium chloride in 200 mL. These experimental beverages were
produced at Asahi Soft Drinks Co., Ltd. (Tokyo, Japan).
2.3. Self-report measurements
The physical and mental health of the participants was subjec-
tively assessed using the following questionnaires: GHQ28, the 28-
item General Health Questionnaire (Goldberg & Hillier, 1979);
HADS, the Hospital Anxiety and Depression Scale (Zigmond &
Snaith, 1983); STAI, the Spielberger State-Trait Anxiety Inventory
(Kvaal, Ulstein, Nordhus, & Engedal, 2005); and PSQI, the Pitts-
burgh Sleep Quality Index (PSQI) (Buysse, Reynolds, Monk,
Berman, & Kupfer, 1989). These questionnaires were given to each
participants at three time points: one week prior to the start of
administration of the beverages and 6 and 12 weeks after the
administration. One week after finishing the administration, the
students took the 3-day national examination and then went on
vacation. We also assessed their mental and physical state 5 weeks
after the examination (19 weeks after starting the manipulation)
when they appeared to be relaxed while on vacation.
2.4. Measurement and assessment of sleep EEG
All subjects underwent overnight EEG monitoring using a
single-channel EEG (SleepScopeTM; SleepWell Co., Osaka, Japan).
This instrument is now approved as a medical equipment (certifi-
cation No. 27ADBZX00087000) in Japan and has been widely used
in recent sleep studies (Goto et al., 2015). The EEG data provided
from the device show high agreement with those from
polysomnography (86.89% with 0.753 k-value). The instrument is
a palm-sized (6.3 cm width  9.4 cm length  3.4 cm depth),
single-channel, portable electroencephalograph with two self-
adhesive electrodes, one to be placed on the forehead and another
to be placed behind the ear. After the participants were instructed
and trained, they wore the portable EEG monitor at home on Tues-
day, Wednesday, and Thursday nights in bed at 3 time points: prior
to the ingestion, 6 and 12 weeks after starting the ingestion. We
treated Tuesday night measurements as a practice. Data collected
on Wednesdays were used for analysis, unless the EEG measure-
ment was not successful on Wednesday in cases of failure in
data-gathering, alcohol intake, and lack of sufficient sleep time
recordings. In those cases, data from Thursday were used. The fol-
lowing indicators of sleep quality were obtained for each subject:sleep latency, total sleep time, sleep efficiency, percentage of wake
after sleep onset (WASO), percentage of stage 3 non-REM (N3)
sleep, and delta power during the first sleep cycle. Scoring of sleep
stages was performed according to the AASM 2007 manual (Berry
et al., 2012).
2.5. Assessments of stool properties and bowel habits
For seven-day periods before the start of administration (base-
line), 6 weeks (mid-term) and 12 weeks (end of ingestion) after
starting the administration, and 7 weeks after finishing the inges-
tion (19 weeks after starting the manipulation) as a relaxed, recov-
ery time, the subjects recorded their physical conditions, stool
properties (form, colour, output, and intensity of odour), frequency
of defecation, feelings after evacuation, and abdominal symptoms.
Faecal form and colour were evaluated in accordance with the Bris-
tol Stool Scale (BSS) (Lewis & Heaton, 1997) and a faecal colour
chart as previously described (Sugawara et al., 2016).
2.6. Assessment of autonomic nerve activities
Autonomic nervous system activity was examined after mea-
suring the variation in the fingertip heart rate (Guideline: heart
rate variability standards, 1996). A TAS9 VIEW (YKC Corporation,
Tokyo, Japan) acceleration pulse wave measurement apparatus,
which is an approved medical device (licence number:
13B3X00442I00001), was used to analyse the heart rate variability.
The autonomic nerve balance analysis conducted at a frequency
level from 0.04 to 0.15 Hz was classified as Low Frequency (LF),
while the analysis conducted at 0.15 to 0.40 Hz was classified as
High Frequency (HF). LF and HF were used as indicators for the
activities of sympathetic and parasympathetic nerves, respectively.
The ratio between LF and HF (LF/HF) or the HF norm parameter,
[HF/(LF + HF)] revealed the overall balance between sympathetic
and parasympathetic nerve activities. The total power (TP, ap-
proximately < 0.4 Hz) was also measured.
2.7. Measurements of salivary cortisol and chromogranin A
Saliva was collected 3 days before and 6 and 12 weeks after
starting test beverage ingestion, as well as 7 weeks after finishing
the ingestion. Saliva samples were collected between 16:00 and
17:00 to avoid diurnal fluctuations using Salivette sampling
devices (Sarstadt Inc., Rommelsdorf, Germany) prior to the
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Salivary chromogranin A (CgA), cortisol and total protein levels
were measured using commercialized enzyme immunoassay kits
(chromogranin A: YK070 Human CgA EIA kit, Yanaihara Institute,
Shizuoka, Japan; cortisol: Expanded Range High Sensitivity Sali-
vary Cortisol Enzyme Immunoassay kit, Salimetrics Inc., LLC, Carls-
bad, CA, USA; total protein: Protein Quantification Kit-Wide Range,
Dojindo Inc., Kumamoto, Japan Ciron, Tokyo, Japan).
2.8. Stress-responsive miRNA levels in peripheral blood leukocytes
We previously reported 7 chronic stress-responsive microRNA
(miR-16, -20b, -26b, -29a, -126, -144, and -144⁄) in peripheral
leukocytes from medical students preparing for the same national
examination for medical practitioners (Honda et al., 2013). Among
them, miR-16, miR-144 and miR-144⁄ levels were also significantly
increased in medical students taking the nationally authorized
examination for promotion (Katsuura et al., 2012). Blood was col-
lected after saliva sampling between 16:00 and 17:00 and immedi-
ately poured into PAXgene-blood RNA tubes (Becton Dickinson,
Franklin Lakes, NJ, USA). Total RNA was prepared, and levels of
miR-16, miR-144 and miR-144⁄ were measured using quantitative
real-time reverse transcription PCR (qPCR) and TaqManR Micro-
RNA assays (Applied Biosystems, Foster City, CA, USA) as previ-
ously described (Honda et al., 2013; Katsuura et al., 2012). All
miRNA data were normalized using RNU48 as the endogenous
quantity control.
2.9. Statistical analyses
Analysis of variance (ANOVA) with split-plot design for
repeated measures and analysis of covariance (ANCOVA) for
repeated measures (panel analysis) was applied to the data
obtained using JMP11 Pro (SAS Institute Japan Ltd., Tokyo, Japan)
and IBM SPSS Statistics ver. 23 (IBM Japan Ltd., Tokyo, Japan).
ANCOVA was used as needed at 12 weeks after the start of inges-
tion as the post hoc test with JMP11 Pro (SAS Institute Japan Ltd.,Table 2
Summary of the results of questionnaires.
Questionnaire Detailed item Factor
Primary
Treatment Sex Treatment  Gender
STAI State anxiety 0.3433 0.0750 0.6815
Trait anxiety 0.4541 0.1972 0.6049
HADS Anxiety 0.3939 0.3700 0.7003
Depression 0.4849 0.6381 0.4930
GHQ Total score 0.1459 0.4402 0.8779
Somatic symptoms 0.4686 0.3875 0.2916
Anxiety/insomnia 0.0561 0.0013 0.0472
Social dysfunction 0.2715 0.4990 0.8793
Severe depression 0.3434 0.8233 0.2692
PSQI Total score 0.2794 0.5890 0.8706
Overall sleep
quality
0.6950 0.8817 0.5838
Sleep latency 0.7999 0.1217 0.4998
Duration of sleep 0.0475 0.4012 0.5097
Sleep efficiency 0.2975 0.8557 0.7667
Sleep disturbance 0.8821 0.5809 0.9792
Need medicine to
sleep
0.0963 0.5335 0.5335
Day dysfunction
due to sleepiness
0.4745 0.8605 0.1778
Data are expressed as the significant probability of the factor calculated by mixed mode
* p < 0.05.
# p < 0.10.Tokyo, Japan). The initial values of each measurement or the
recorded items measured before the manipulation were employed
as covariates.
3. Results
3.1. Effects of paraprobiotic CP2305 on physical and mental state
The results of the questionnaires are summarized in Table 2.
The mean values of the STAI-state scores measured at 0 week
(14 weeks before the examination) were already higher than the
threshold value of 40 in the Japanese version of STAI (Nakazato &
Shimonaka, 1989), gradually increased to 55–60 at 12 weeks
(2 weeks before the examination), and returned to normal (base-
line) levels at 19 weeks (5 week after the examination) (Fig. 2A).
The mean values of GHQ-28 general score measured at 0, 6, and
12 weeks were above the threshold value of 5, and then, they
returned to normal levels at 19 weeks (5 weeks after the examina-
tion) (Fig. 2B). Generally, a majority of medical students feel pres-
sure and become anxious more than 6 months before the
examination. The medical students felt anxiety and complained
of physical symptoms for more than 14 weeks. Thus, we confirmed
that the paraprobiotic CP2305 was administered during this long-
term stressful situation.
The STAI-state scores were not significantly different between
the paraprobiotic CP2305 and placebo groups through the trial per-
iod (Fig. 2A left). However, female students showed significantly
higher initial STAI-state scores and more extensive elevation of
the score compared with that of male students (Tables 1 and 2).
Moreover, a significant difference in the scores between the two
groups was observed in female students 12 weeks after the start
of ingestion by ANCOVA with their initial scores as the covariance
[p = 0.0346 (ANCOVA); Fig. 2A right]; the paraprobiotic CP2305
significantly prevented the elevation of the STAI-state scores
2 weeks before the examination. A significant difference in the
total score (p = 0.0468; Fig. 2B left) of the GHQ-28 general score
was also observed in female volunteers from the post hoc analysesSecondary
Time Time  Treatment Time  Sex Time  Group  Gender Initial
score
<0.0001 0.8417 0.0197* 0.5607 <0.0001
0.2760 0.9309 0.6495 0.5301 <0.0001
0.0430 0.6935 0.1782 0.7461 <0.0001
0.0101 0.8429 0.8601 0.2439 <0.0001
0.1479 0.8363 0.7936 0.9641 <0.0001
0.8162 0.3968 0.8401 0.9656 <0.0001
0.0147 0.7080 0.0748# 0.7361 <0.0001
0.5956 0.9855 0.9275 0.7301 <0.0001
0.6489 0.2857 0.2118 0.8320 <0.0001
0.4343 0.0281* 0.2807 0.7376 <0.0001
0.5424 0.0333* 0.8700 0.7035 <0.0001
0.7246 0.6773 0.1798 0.9835 <0.0001
0.1467 0.0286* 0.0379* 0.0920# <0.0001
0.2098 0.3242 0.9468 0.8385 <0.0001
0.9223 0.4570 0.3151 0.1764 <0.0001
0.2408 0.2408 0.6646 0.6646 <0.0001
0.7412 0.3541 0.5947 0.3551 <0.0001
l ANOVA for repeated measures.
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Fig. 2. Changes in stress-related behaviours as inferred from the questionnaires. (A) Time-dependent changes in the STAI-state anxiety score in female participants. ANCOVA
showed a significant difference between the groups at the end of the ingestion period. (B) Changes in the GHQ28 total score in female volunteers. At the end of the ingestion
period, ANCOVA indicated a significant difference between groups (right panel). Open circles (s) and short dashed lines represent the placebo group, and closed circles (d)
and solid lines represent the paraprobiotic CP2305 group. Ovals express 0.95 density ellipses, and lines inside of ovals are regression lines.
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right). Additionally, paraprobiotic CP2305 suppressed the increase
in the general scores.
In the PSQI questionnaire, the paraprobiotic CP2305 group
showed desirable changes compared with those of the placebo
group in total score (p = 0.0281), overall sleep quality (p = 0.0333),
and duration of sleep (p = 0.0286) (Fig. 3A-C). There was no signifi-
cant difference between both groups in sleep efficiency, while a sig-
nificant difference was observed at 12 weeks by ANCOVA when
their initial values were used as covariates (p = 0.0044; Fig. 3D).
The sleep latency was also significantly different in female volun-
teers at 12 weeks by ANCOVA (p = 0.0234; data not shown).
Both anxiety and depression scales of the HADS were signifi-
cantly increased during the pre-examination, and its anxiety scale
was more profoundly elevated in female than male students
(Table 2). However, we could not detect any significant differences
in the HADS scores between the CP2305 and the placebo groups
(Table 2).3.2. Assessment of sleep quality using EEG
We could not measure EEG after the examination because most
students had long vacations. We therefore measured sleep EEGbefore (0) and 6 or 12 weeks after starting the ingestion and exam-
ined how the CP2305 administration affected their sleep. Com-
pared with the placebo intake, the CP2305 intake significantly
decreased sleep latency (p < 0.001; Fig. 4A), prevented the reduc-
tion of the total d power (high-amplitude slow wave: 0.5–2 Hz,
75 mV) for one minute during sleeping time (p < 0.001; Fig. 4B),
and increased the appearance of the fraction of stage N3 in the
non-REM sleep period (p < 0.001; Fig. 4C) during the pre-
examination period. In addition, the number of awakenings in
the 2 h before wake-up was significantly decreased (p < 0.001;
Fig. 4D). Notably, the incremental trend in the number of awaken-
ings in volunteers who had a low initial number of awakenings
with time was controlled by CP2305 administration.3.3. Effects of paraprobiotic CP2305 on salivary stress markers
As shown in Fig. 5A, ANCOVA for repeated measures with the
initial value of the concentration as the covariate revealed that
the paraprobiotic CP2305 ingestion significantly suppressed the
escalation of salivary cortisol levels as time progressed
(p < 0.001) compared with that of the placebo intake. ANCOVA
was applied to each time point as a post hoc test. Significant
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and 12 (p = 0.0087) weeks after starting the ingestions.
We could not detect any time-dependent change and group dif-
ference in salivary chromogranin A levels (data not shown).3.4. Effects of paraprobiotic CP2305 on autonomic nervous activities
Repeated-measures ANCOVA showed a significant difference in
the HF/(HF + LF) value (HF norm) between the paraprobiotic
CP2305 and the placebo groups, as shown in Fig. 5B. The HF norm
value, which represents the relative parasympathetic nervous
activity, was increased by ingestion of the beverage containing
the paraprobiotic CP2305 (p < 0.001; Fig. 5B).3.5. Paraprobiotic CP2305 and bowel movement
Paraprobiotic CP2305 ingestion normalized the defecation fre-
quency under stressful conditions; the frequency in the parabiotic
CP2305 group was closer to the seven times per week of ideal
bowel movements (p < 0.001; Fig. 6A). These results were similar
to the results of past clinical trials (Sawada et al., 2016;Sugawara et al., 2016). Notably, there was clear decrement in stool
frequency in male participants who had a high frequency of pas-
sage at the start of the trial (data not shown).
When stool properties were evaluated with the BSS, the shape
of the faeces effectively moved closer to a value of 4 after taking
the paraprobiotic CP2305, but not the placebo, even under stressful
conditions (p < 0.001; Fig. 6B). Thus, stool shapes became normal-
ized in the paraprobiotic CP2305 group. Consequently, daily faecal
output was also favourably changed with the paraprobiotic CP2305
(p < 0.001; Fig. 6C); the average amount of defecation per day was
altered to the equivalent of approximately 4 moquettes in the
paraprobiotic CP2305 group.3.6. Expression of stress-responsive microRNAs in peripheral blood
leukocytes
MiR-144, miR-144⁄, and miR-16 in circulating leukocytes were
identified as stress-responsive microRNAs in healthy medical stu-
dents exposed to a chronic stress model (Honda et al., 2013) in this
study and to an acute stress model (Katsuura et al., 2012). Daily
intake of the paraprobiotic CP2305 significantly suppressed the
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(p = 0.0117; Fig. 7B), compared with that of the placebo intake. This
suppressive effect was not observed in miR-16 (p = 0.1931;
Fig. 7C). A repeated-measures ANOVA showed that ‘‘sex” was an
important factor for the changes in the expressions of these micro-
RNAs. Although the paraprobiotic CP2305 similarly reduced the
miR-144⁄ expression in both male and female students (data not
shown), the effect of paraprobiotic CP2305 on miR-144 was
observed in female students (p = 0.0118) but was absent in male
students (p = 0.9357).
4. Discussion
The term ‘‘psychobiotics” was recently defined as ‘‘live
microbes that have a positive mental health benefit” (Dinan
et al., 2013). Several recent studies in healthy subjects suggest that
certain bacterial strains have a psychobiotic activity (Romijn &
Rucklidge, 2015). In this manner, B. longum strain 1714 improved
stress responses and enhanced cognition in healthy subjects while
altering their EEG (Allen et al., 2016). In addition, a cocktail of pro-
biotics was shown to significantly change brain function, asdemonstrated with functional MRI (Tillisch et al., 2013). Until very
recently, however, the probiotics literature for stress relief was
dominated by animal studies with little effort to translate this
work into humans. In addition, there is an example that a probiotic
Lactobacillus rhamnosus JB-1 with promising preclinical evidence
(Bravo et al., 2011) failed to translate to healthy human partici-
pants (Kelly et al., 2017). There is a strong need for translational
studies in human subjects, and for that reason, the current study
may be of interest.
In this study, we tried to expand the above concept of ‘‘psy-
chobiotics” to ‘‘para-psychobiotics”. For this purpose, we used
heat-inactivated and washed CP2305 as a paraprobiotic to confirm
its stress-relief effects on healthy young adults. The paraprobiotic
CP2305 is also useful for understanding the mechanism(s) of psy-
chobiotic actions. We previously reported the beneficial effects of
live CP2305 on the clinical symptoms and the QOL of IBS patients
(Nobutani et al., 2017). We also showed the beneficial effects of
live CP2305 on anxiety, depression, and sleep disturbances in med-
ical students taking a cadaver dissection course (Sawada et al.,
2017). However, these trials were carried out with live CP2305
and only for a short ingestion period of 4 weeks. We therefore
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associated behaviours in a long-term dosage period of 12 weeks.
Medical students preparing for the national examination for
medical practitioners were accepted as a useful model for studying
chronic psychological stress responses (Honda et al., 2013;
Kurokawa et al., 2011). In this study, samples were taken at four
time points: prior to ingestion, 6 and 12 weeks after ingestion
had started, and 7 weeks after termination of the ingestion (post-
ingestion period). All subjects in this study were newly recruited.
Consistent with the previous reports (Honda et al., 2013;
Kurokawa et al., 2011), the students in this study felt pressure even
at the initial sampling time (0); the mean values of the STAI-state
and the PSQI-general scores were above their threshold values. The
STAI-state score gradually increased, and the general GHQ-28 score
remained elevated during the pre-examination period. Both scores
returned to normal levels 5 weeks after the examination
(19 weeks). Thus, we confirmed that paraprobiotic CP2305 was
administered under chronically stressed conditions.
We first examined whether the daily administration of the
paraprobiotic CP2305 improved self-reported measures of physical
and psychological state. As described above, the situation resulted
in high scores in the questionnaires at the start of the trial; the ini-
tial scores in GHQ-28, STAI, and HADS were over their thresholds.
The differences in these scores between both groups may not be
distinguishable. Another important concern is to consider the
sex-dependent symptoms and sensitivity to CP2305 intake. Female
students showed greater increases in the STAI-state and the gen-
eral GHQ-28 scores than male students did, and the CP2305 intake
significantly suppressed these increases only in female students.
However, female students did not show changes in their bowel
habits and stool properties, while male students significantly
increased the incidence of diarrhoea. The CP2305 intake effectively
improve their bowel movements and stool properties. Thus, there
may be sexual differences in the appearance of stress-associated
symptoms. The paraprobiotic CP2305 intake appeared to effec-
tively suppress the stress-associated symptoms in both sexes. To
address these issues, we should analyse larger numbers of partici-
pants of both sexes at more appropriate sampling times.
All medical students have to pass the national medical license
examination to become clinical physicians. This examination con-
sists of a three-day test and is the most stressful and important
event for medical students. Because of this difficult study period
in a special environment, the students had progressively com-
plained of sleep disturbance, particularly in the placebo group.
Notably, paraprobiotic CP2305 administration significantly
improved sleep disturbance under this long-term stressful situa-
tion. Sleep quality is an outcome that comprehensively reflects
both physical and psychological conditions (Mollayeva et al.,
2016). In a recent study (Sawada et al., 2017), we observed similar
improvement of sleep disturbance with live CP2305 in medical stu-
dents taking a cadaver dissection course, which was also assessed
with the PSQI. The beneficial effects on sleep quality were again
observed even with paraprobiotic CP2305, indicating the potential
benefits of this strain for mental health promotion. This time, the
effect was objectively confirmed by sleep EEG monitoring. The d
power is an indicator of depth of sleep. An epoch (30 s of sleep)
that consists of 20% or more slow-wave d sleep is considered to
be stage three depth of sleep. Daily intake of paraprobiotic
CP2305 increased the ratio of the slow-wave stage, even under
chronically stressful conditions. Paraprobiotic CP2305 shortened
sleep latency, increased d power and N3 stage sleep, and main-
tained sleep, resulting in suitable sleep time.
In addition to this important finding on sleep EEG monitoring,
we confirmed another interesting physiological effect of paraprobi-
otic CP2305 on the parasympathetic nervous system. Autonomic
nervous activities were evaluated using a pulse analyser, TAS9-VIEW (YKC Group, Tokyo, Japan). Daily intake of paraprobiotic
CP2305, but not placebo, preferentially increased the rate of
parasympathetic nerve activity (HF norm) during the pre-
examination period. This effect may also be associated with the
stress-relief effects of the paraprobiotic CP2305. In fact, in associa-
tion with the improvement of parasympathetic nerve activity, the
paraprobiotic CP2305 intake improved bowel habits and stool
properties, and it also effectively suppressed the escalation of basal
salivary cortisol levels during the pre-examination period. Salivary
cortisol level reflects the HPA axis activity and the sympathetic
nervous system. Increased salivary cortisol levels measured in
early evening (basal levels) are associated with mental distress.
In the parameters of gut function, paraprobiotic CP2305 regulated
the frequency of the bowel movement to the ideal condition. Para-
probiotic CP2305 acted as an effective antiflatulent, particularly in
male students. Male students gradually developed loose bowel-like
symptoms in the placebo group, which were ameliorated by the
CP2305 administration, as observed in previous studies (Sawada
et al., 2016; Sugawara et al., 2016). Consequently, after the 12-
week administration, faecal samples of all participants had a nor-
mal stool shape (close to score 4 on the BSS). These data indicate
that CP2305 could exert sufficient effects on the gut function even
in the paraprobiotic form. The next important step is to clarify the
active material(s) of the bacterium and the mechanism of its effect
on the gut-brain axis.
Finally, we assessed the beneficial effects of paraprobiotic
CP2305 by measuring a different type of biological stress marker.
For this purpose, we measured psychological stress-responsive
microRNAs. MicroRNAs play key roles in the regulation of cellular
processes in response to changes in the environment. Using the
same chronic stress model (students preparing for the national
examination for medical practitioners), we identified miR-144,
miR-144⁄ and miR-16 as stress-responsive microRNAs (Honda
et al., 2013). MiR-144 modulates oxidative stress, and miR-16 inhi-
bits the expression of the serotonin transporter (Baudry, Mouillet-
Richard, Schneider, Launay, & Kellermann, 2010; Katsuura et al.,
2012; Sangokoya, Marilyn, & Chi, 2010). The daily intake of para-
probiotic CP2305 suppressed elevation of miR-144 and -144⁄
expression compared with that of the placebo intake. The micro-
RNA responses also showed sexual differences. When the effect
of paraprobiotic CP2305 was examined independently in male
and female students, CP2305 significantly suppressed the stress-
induced elevation of miR-144 and miR144⁄ in female students,
while these effects were absent in male students.
The present study reports the potential stress-relieving effect of
paraprobiotic CP2305 using several objective measurements. How-
ever, it is unclear how the daily intake of the heat-inactivated and
washed bacterial cells could affect the gut-brain axis and alter the
stress responses. One possible route of the communication is
through the vagal nerve. We attempted to address this possibility
and found that an intragastric ingestion of the preparation could
activate the afferent vagal nerve from the stomach or the intestine
in rats (unpublished observations). We also repeatedly confirmed
that the CP2305 strain has an enteric-colonizing ability after its
oral administration. These findings support the following novel
hypothesis. This strain may bind a responsible receptor(s) on
intestinal epithelial or other cells and promote the dispatch of a
signal(s) driving the HPA axis. Studies on the purification of the
bioactive substance(s) of CP2305 are now in progress.5. Conclusions
In conclusion, paraprobiotic CP2305 was demonstrated to have
beneficial effects on medical students under chronically stressful
conditions. Administration of paraprobiotic CP2305 significantly
K. Nishida et al. / Journal of Functional Foods 36 (2017) 112–121 121ameliorated their stress-related adverse behaviours and improved
sleep disturbance. Our results suggest that the paraprobiotic has
potential benefits for mental health promotion. To the best of our
knowledge, the paraprobiotic strain described in this report is
the first-reported ‘‘para-psychobiotic”.
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